GlassScriptPhysician profile
Juan Carlos Barragan
NPI 1962401190
$3,165.77
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $347 · 2021: $436 · 2022: $485 · 2023: $752 · 2024: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,139.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $255.00 | 2021-2024 | Krystexxa |
| Merck Sharp & Dohme LLC | $254.41 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $251.98 | 2022-2023 | Diamondback Peripheral |
| Horizon Therapeutics Plc | $248.71 | 2022-2023 | Krystexxa |
| Smith+Nephew, INC. | $224.28 | 2019-2023 | Renasys Go V2 Home |
| Paratek Pharmaceuticals, INC. | $173.85 | 2022-2023 | Nuzyra |
| Rikco International, LLC | $170.00 | 2019 | |
| Treace Medical Concepts, INC. | $155.18 | 2022 | |
| Aroa Biosurgery Incorporated | $153.21 | 2020 | |
| Kerecis Limited | $149.74 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Misonix INC | $131.95 | 2021 | |
| Averitas Pharma INC. | $130.00 | 2024 | Qutenza |
| Polynovo North America LLC | $127.13 | 2024 | Novosorb Btm |
| Tactile Systems Technology INC | $125.53 | 2020-2021 | |
| Leo Pharma INC. | $125.04 | 2023 | Adbry |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $125.00 | 2021 | |
| Wright Medical Technology, INC. | $97.89 | 2019 | |
| Medtronic Vascular, INC. | $86.31 | 2019 | |
| Melinta Therapeutics, LLC | $52.90 | 2019 | |
| Nevro Corp. | $46.44 | 2022-2023 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.43 | 2022 | |
| Glaxosmithkline, LLC. | $14.17 | 2019 | |
| Avanir Pharmaceuticals, INC. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Barragan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.